Navigation Links
Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers

PITTSBURGH, Feb. 4 Researchers at the University of Pittsburgh and their collaborators have been awarded a $5.6 million federal contract to pursue the continued development of an implanted ventricular assist heart pump for infants and small children with congenital or acquired heart disease. The project aims to provide much-needed access to the sophisticated technologies that have saved the lives of older heart failure patients.

Harvey Borovetz, Ph.D., distinguished professor and chair of the Department of Bioengineering and a deputy director of the McGowan Institute for Regenerative Medicine, is the principal investigator of one of four projects that comprise the Pumps for Kids, Infants and Neonates (PumpKIN) Preclinical Program, a $23.6 million effort sponsored by the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI). He and his colleagues at Pitt, Children's Hospital of Pittsburgh of UPMC, Carnegie Mellon University, Goleta, California-based LaunchPoint Technologies, and Salt Lake City-based WorldHeart Inc., began designing and building their device, called PediaFlow, more than five years ago.

"We now have the opportunity to put PediaFlow through the necessary development and testing needed to proceed to clinical trials," Dr. Borovetz explained. "The aim is to begin human studies in three to four years."

According to the NHLBI, nearly 1,800 American infants die annually due to congenital heart defects. Another 350 develop severe cardiomyopathy leading to heart failure. Each year, approximately 60 children younger than age 5 waiting on the heart transplant list may die before a donor organ becomes available.

PediaFlow, which is made of a titanium alloy and is about the size of an AA battery, incorporates innovative mag-lev technology. Blood is drawn through it by means of a high-speed rotor that essentially floats within its housing due to magnetic levitating forces. The rotor geometry, which is designed using state-of-the-art computer models and analyses, pulls oxygenated blood from the left ventricle through the device, returning the blood to the aorta and patient circulation. The flow rate of the PediaFlow can be varied between 0.5 to 1.5 liters per minute, suitable for the very smallest infants to toddlers.

"We believe the PediaFlow will be capable of replacing the heart function of our smallest patients," explained Peter Wearden, M.D., Ph.D., a cardiothoracic surgeon at Children's Hospital who leads the clinical work of the project. "Left ventricular assist devices (LVADs) have been very successful in supporting older children and adults as a bridge to eventual heart transplantation, or, in some cases, as a temporary measure that allows the heart to rest and recover. But there currently are no FDA-approved LVADs for babies and toddlers."

Extracorporeal membrane oxygenation, or ECMO, currently is the only form of support for these smallest of children, but it requires that patients be fully anesthetized, and can only be used for a few weeks before severe complications develop.

"This creates a 'race against time' while we and the family wait for an appropriate donor organ to become available," Dr. Wearden noted. "To meet the NHLBI's requirements, PediaFlow must support patients for up to six months, and our preclinical research has already shown that it works flawlessly for at least 70 days. We are very excited to have these additional resources to help bring this technology to these children."

The other PumpKIN contractors are Mark Gartner, Ph.D., of Ension Inc., Pittsburgh, Pa.; Bartley P. Griffith, M.D., University of Maryland, Baltimore; and Robert Jarvik, M.D., Jarvik Heart Inc., New York, N.Y.

"This research seeks to develop technologies to expand life-saving options for infants and children born with congenital heart defects or those who develop heart failure," said Susan B. Shurin, M.D., a pediatrician and acting director of the NHLBI. "Similar devices are in use in adults. Well-designed circulatory support could dramatically improve the outcomes of these young patients as they seek to recover or wait to receive a heart transplant."


Contact: Anita Srikameswaran
University of Pittsburgh Schools of the Health Sciences

Related biology news :

1. Pitt-led researchers create quick, simple fluorescent detector for TB
2. Structure of 450 million year old protein reveals evolutions steps
3. First orchid fossil puts showy blooms at some 80 million years old
4. SyntheMed Completes $2.8 Million Equity Financing
5. Rutgers Genetics receives $7.8 million for autism research
6. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
7. UD leads $5.3-million research project on rice epigenetics
8. Rutgers high school outreach gets $3 million boost from NSF
9. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
10. UD leads $5.3-million research project on rice epigenetics
11. $22 million gift from Alfred Taubman launches new biomedical research institute
Post Your Comments:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology: